Research Publications and Outputs: Recent submissions
-
Mentally Healthy Futures Project submission to the Standing Committee on Social Issues: Inquiry into the prevalence, causes and impacts of loneliness in New South Wales
This report includes a policy submission from members of the Mentally Healthy Futures Project (The Matilda Centre, University of Sydney) to the Standing Committee on Social Issues: Inquiry into the prevalence, causes and ...Open AccessSubmission to government/public bodies/organisations -
Tumor-infiltrating lymphocyte grade (TIL grade) is an independent predictor of sentinel lymph node status and survival in cutaneous melanoma patients
Published 2012Purpose: To determine whether density and distribution of tumor-infiltrating lymphocytes (TIL) (TIL grade) is an independent predictor of sentinel node (SLN) status and survival in patients with clinically localized primary ...Open AccessArticle -
PD-L1 expression in melanoma has prognostic significance but shows marked heterogeneity within and between patients- implications for anti-PD-1/PD-L1 clinical trials
Published 2015This study evaluated the expression of PD-L1 in immunotherapy-naive metastatic melanoma patients to determine longitudinal intrapatient concordance and correlate PD-L1 status with clinicopathologic characteristics and ...Open AccessArticle -
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
Published 2015BACKGROUND: Adjuvant radiotherapy is recommended for patients with melanoma after lymphadenectomy. We previously showed this treatment reduced risk of repeat lymph-node field cancer in patients with a high risk of recurrence ...Open AccessArticle -
CD103(+) Tumor-Resident CD8(+) T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Published 2018Purpose: Therapeutic blockade of immune checkpoints has revolutionized cancer treatment. Durable responses, however, occur in less than half of those treated, and efforts to improve treatment efficacy are confounded by a ...Open AccessArticle